This protocol applies to infants with cryptogenic infantile spasms — those with normal neurodevelopment prior to the onset of spasms, no identifiable structural or metabolic etiology, and no tuberous sclerosis.
First-line hormonal therapy was initiated but did not achieve complete cessation of clinical spasms and resolution of hypsarrhythmia on video EEG — the two primary goals assessed typically within 14 days. This protocol describes the next step when that threshold is not met.
Complete cessation of spasms and full resolution of hypsarrhythmia on video EEG, typically assessed within 14 days of initiating therapy.
DOI: 10.3978/j.issn.2224-4336.2015.09.01
Defines symptomatic infantile spasms as those patients with either abnormal development and/or a clear etiology for the infantile spasms and cryptogenic spasms as those occurring in the context of normal development without a clear etiology.
For example, patients with tuberous sclerosis are more likely to respond to treatment with vigabatrin, whereas patients without an identified etiology may respond better to hormonal therapy.
It is recommended to try two first-line therapies before moving on to other options, as there is less data to support the second-line treatments.
Studies have reported patients that respond to ACTH after failing corticosteroids and vice-versa.
The goals of therapy should include a complete cessation of the clinical events and resolution of hypsarrhythmia or modified hypsarrhythmia on video EEG.
Response is typically seen within 14 days or sooner.
View source ↗